Increasing awareness of hypoglycaemia in patients with type 2 diabetes treated with oral agents

Current Medical Research and Opinion

Volumn 29, Issue 11, 2013, Pages 1503-1513

  Barnett, A H ^a   Brice, R ^b   Hanif, W ^c   James, J ^d   Langerman, H ^e  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b Whitstable Medical Practice   (United Kingdom)

^c UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^d LEICESTER ROYAL INFIRMARY   (United Kingdom)

^e MSD ^*  (United Kingdom)

Author keywords

Education; Hypoglycaemia; Prevention; Risk factor; Sulphonylurea; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

AGE DISTRIBUTION; ALCOHOL CONSUMPTION; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; DIET RESTRICTION; DISEASE ASSOCIATION; DRIVING ABILITY; EMPLOYMENT; GLUCONEOGENESIS; GLUCOSE UTILIZATION; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH PROMOTION; HUMAN; HYPOGLYCEMIA; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DELAYED DIAGNOSIS; DIABETES MELLITUS, TYPE 2; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; RENAL INSUFFICIENCY; RISK FACTORS; SULFONYLUREA COMPOUNDS;

EID: 84885695140     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.834250     Document Type: Review

References (79)

1. Barnett AH, Cradock S, Fisher M, et al. Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. Int J Clin Pract 2010;64:1121-9
2. Wild D, von Maltzahn R, Brohan E, et al. A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education. Patient Educ Couns 2007;68:10-15 (Pubitemid 47126791)
3. Inzucchi SE, Inzucchi SE, Bergenstal RM, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:157715-96
4. Burge MR, Chelliah A, Schade DA. Hypoglycemia in type 2 diabetes mellitus. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes Mellitus: A Fundamental and Clinical Text, 3rd edn. Philadelphia, USA: Lippincott Williams & Wilkins, 2004, 83:1213-24
5. Segel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes 2002;51:724-33 (Pubitemid 34760182)
6. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 2002;45:937-48 (Pubitemid 34762188)
7. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005;28:2948-61 (Pubitemid 43942931)
8. UK Hypoglycemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140-7
9. Cryer PE. The barrier of hypoglycaemia in diabetes. Diabetes 2008;57: 3169-76
10. Alvarez Guisasola F, Tofé Povedano S, Krishnarajah G, et al. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab 2008;10(Suppl 1):25-32
11. Tschö pe D, Bramlage P, Binz C, et al. Incidence and predictors of hypoglycaemia in type 2 diabetes-an analysis of the prospective DiaRegis registry. BMC Endocr Disord 2012;12:23
12. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147:386-99 (Pubitemid 351664540)
13. Fisher M. Hypoglycaemia in patients with type 2 diabetes: minimizing the risk. Br J Diabetes Vasc Dis 2010;10:35-41
14. Gangji AS, Cukierman T, Gerstein HC, et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events. A comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007;30:389-94 (Pubitemid 46198354)
15. Asplund K, Wiholm BE, Lithner F. Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia 1983;24:412-17
16. Campbell IW. Sulfonylureas and hypoglycemia. Diabetic Hypoglycemia 2009;2:3-10
17. Wright AD, Cull CA, Macleod KM, Holman RR; for the UKPDS Group. Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J Diabetes Complications 2006;20:395-401 (Pubitemid 44740219)
18. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59 (Pubitemid 351831356)
19. Krobot KJ, Ferrante SA, Davies MJ, et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value. Curr Med Res Opin 2012;28:1281-7
20. Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1121-7
21. Arem R. Hypoglycemia associated with renal failure. Endocrinol Metab Clin North Am 1989;18:103-21 (Pubitemid 19058104)
22. Dickerson RN, Hamilton LA, Connor KA, et al. Increased hypoglycemia associated with renal failure during continuous intravenous insulin infusion and specialized nutritional support. Nutrition 2011;27:766-72
23. Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev 2008;24:353-63
24. Frier BM, Schernthaner G, Heller SR. Hypoglycemia and cardiovascular risks. Diabetes Care 2011;34(Suppl 2):S132-7
25. Choudhary P, Amiel SA. Hypoglycaemia: current management and controversies. Postgrad Med J 2011;87:298-306
26. Waheed N, Butt M, Dayan C. Hypoglycaemia documented with real-time continuous glucose sensing in a case of 'dead in bed' syndrome. Pract Diabetes Int 2013;30:33-5
27. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909
28. Unger J. Uncovering undetected hypoglycemic events. Diabetes Metab Syndr Obes 2012;5:57-74
29. ADVANCE Collaborative Group; Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72 (Pubitemid 351831357)
30. Duckworth WC, Abraira C, Moritz TE, et al.; Investigators of the VADT. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. J Diabetes Complications 2011;25:355-61
31. Desouza C, Salazar H, Cheong B, et al. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 2003;26:1485-9 (Pubitemid 36929183)
32. Hsu P-F, Sung S-H, Cheng H-M, et al. Association of clinical symptomatic hypoglycemia with cardiovascular events and total mortality in type 2 diabetes. A nationwide population-based study. Diabetes Care 2013;36: 894-900
33. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
34. Zhang Q, Marrett E, Jameson K, et al. Reasons given by general practitioners for non-treatment decisions in younger and older patients with newly diagnosed type 2 diabetes mellitus in the United Kingdom: a survey study. BMC Endocr Disord 2011;11:17
35. Matyka K, Evans M, Lomas J, et al. Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care 1997;20:135-41 (Pubitemid 27051549)
36. Marker JC, Cryer PE, Clutter WE. Attenuated glucose recovery from hypoglycemia in the elderly. Diabetes 1992;41:671-8
37. Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults. Diabetes Care 2012;35:2650-64
38. Brice R, Langerman H, Barnett AH, James J. A pharmacy-led patient survey suggests significant deficiencies in education regarding the risks of hypoglycaemia in sulphonylurea-treated patients with type 2 diabetes. Abstract presented at the Diabetes UK 2013 Professional Conference, Manchester, UK, 13-15 March, 2013
39. Punthakee Z, Miller ME, Launer LJ, et al.; ACCORD-MIND Investigators. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care 2012;35:787-93
40. Sinclair A, Morley JE, Rodriguez-Mañ as L, et al. Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J Am Med Dir Assoc 2012;13:497-502
41. Salti I, Benard E, Detournay B, et al.; the EPIDIAR Study Group. A populationbased study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the Epidemiology of Diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care 2004;27:2306-11 (Pubitemid 39281377)
42. Aravind SR, Al Tayeb K, Ismail SB, et al.; 2009 Ramadan Study Group. Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study. Curr Med Res Opin 2011;27:1237-42
43. Hassanein M, Hanif W, Malik W, et al. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study. Curr Med Res Opin 2011;27:1367-74
44. Aravind SR, Ismail SB, Balamurugan R, et al. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study. Curr Med Res Opin 2012;28:1289-96
45. Al Sifri S, Basiounny A, Echtay A, et al.; 2010 Ramadan Study Group. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. Int J Clin Pract 2011;65:1132-40
46. Al-Arouj M, Assaad-Khalil S, Buse J, et al. Recommendations for management of diabetes during Ramadan: update 2010. Diabetes Care 2010;33:1895-902
47. Hui E, Bravis V, Hassanein M, et al. Management of people with diabetes wanting to fast during Ramadan. BMJ 2010;340:1407-11
48. Ahmad J, Pathan MF, Jaleel MA, et al. Diabetic emergencies including hypoglycemia during Ramadan. Indian J Endocrinol Metab 2012;16:512-15
49. Aldasouqi S, Sheikh A, Klosterman P, et al. Hypoglycemia in patients with diabetes on antidiabetic medications who fast for laboratory tests. Diabetes Care 2011;34:e52
50. Kerr D, Macdonald IA, Heller SR, Tattersall RB. Alcohol causes hypoglycaemic unawareness in healthy volunteers and patients with Type 1 (insulin-dependent) diabetes. Diabetologia 1990;33:216-21 (Pubitemid 20136238)
51. Huang Z, Sjö holm A. Ethanol acutely stimulates islet blood flow, amplifies insulin secretion, and induces hypoglycemia via nitric oxide and vagally mediated mechanisms. Endocrinology 2008;149:232-6
52. Burge MR, Zeise T-M, Sobhy TA, et al. Low-dose ethanol predisposes elderly fasted patients with type 2 diabetes to sulfonylurea-induced low blood glucose. Diabetes Care 1999;22:2037-43 (Pubitemid 30433985)
53. Frier BM. Impaired hypoglycaemia awareness. In: Frier BM, Fisher M, eds. Hypoglycaemia in Clinical Diabetes, 2nd edn. Chichester: John Wiley & Sons, 2007:141-70
54. Lundkvist J, Berne C, Bolinder B, Jonsson L. The economic and quality of life impact of hypoglycemia. Eur J Health Econ 2005;6:197-202 (Pubitemid 41638842)
55. Frier BM. How hypoglycaemia can affect the life of a person with diabetes. Diabetes Metab Res Rev 2008;24:87-92 (Pubitemid 351284751)
56. Williams SA, Shi L, Brenneman SK, et al. The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients. J Diabetes Complications 2012;26:399-406
57. Vexiau P, Mavros P, Krishnarajah G, et al. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. Diabetes Obes Metab 2008;10:16-24
58. Marrett E, Radican L, Davies MJ, Zhang Q. Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: a survey study. BMC Res Notes 2011;4:251
59. Holmes CS, Hayford JT, Gonzalez JL, Weydert JA. A survey of cognitive functioning at difference glucose levels in diabetic persons. Diabetes Care 1983;6:180-5 (Pubitemid 13160970)
60. Cox DJ, Gonder-Frederick LA, Kovatchev BP, et al. Progressive hypoglycemia's impact on driving simulation performance. Occurrence, awareness and correction. Diabetes Care 2000;23:163-70 (Pubitemid 30071018)
61. Cox DJ, Gonder-Frederick L, Clarke W. Driving decrements in type I diabetes during moderate hypoglycemia. Diabetes 1993;42:239-43 (Pubitemid 23045026)
62. DVLA. Information for drivers with diabetes treated by non insulin medication, diet, or both. Available at: http://www.direct.gov.uk/prod-consum- dg/groups/dg-digitalassets/@dg/@en/@motor/documents/digitalasset/dg-067957.pdf [Last accessed November 2012]
63. Brod M, Pohlman B, Wolden M, Christensen T. Non-severe nocturnal hypoglycemic events: experience and impacts on patient functioning and wellbeing. Qual Life Res 2013;22:997-1004
64. Veneman T, Mitrakou A, Mokan M, et al. Induction of hypoglycemia unawareness by asymptomatic nocturnal hypoglycemia. Diabetes 1993;42:1233-7 (Pubitemid 23259841)
65. Brod M, Christensen T, Bushnell DM. Impact of nocturnal hypoglycemic events on diabetes management, sleep quality, and next-day function: results from a four-country survey. J Med Econ 2012;15:77-86
66. Curkendall SM, Zhang B, Oh KS, et al. Incidence and cost of hypoglycemia among patients with type 2 diabetes in the United States: analysis of a health insurance database. J Clin Outcomes Manage 2011;18:455-62
67. Hex N, Bartlett C, Wright D, et al. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabetic Medicine 2012;29:855-62
68. Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011;14:665-71
69. Hammer M, Lammert M, Mej́as SM, et al. Costs of managing severe hypoglycaemia in three European countries. J Med Econ 2009;12:281-90
70. Brackenridge A, Wallbank H, Lawrenson RA, Russell-Jones D. Emergency management of diabetes and hypoglycaemia. Emerg Med J 2006;23: 183-5 (Pubitemid 44295343)
71. Farmer AJ, Brockbank KJ, Keech ML, et al. Incidence and costs of severe hypoglycaemia requiring attendance by the emergency medical services in South Central England. Diabet Med 2012;29:1447-50
72. Nirantharakumar K, Marshall T, Kennedy A, et al. Hypoglycaemia is associated with increased length of stay and mortality in people with diabetes who are hospitalized. Diabet Med 2012;29:e445-8
73. Hospital Episode Statistics. Available at: http://www.hesonline.nhs.uk [Last accessed March 2013]
74. Skyler JS, Bergenstal R, Bonow RO, et al.; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009;53:298-304
75. National Institute for Health and Clinical Excellence. NICE clinical guideline. Type 2 diabetes. The management of type 2 diabetes. Available at: http://www.nice.org.uk/nicemedia/live/12165/44320/44320.pdf [Last accessed 11 March 2013]
76. Freckmann G, Schmid C, Baumstark A, et al. System accuracy evaluation of 43 blood glucose monitoring systems for self-monitoring of blood glucose according to DIN EN ISO 15197. J Diabetes Sci Technol 2012;6:1060-75
77. American Diabetes Association. Statement by the American Diabetes Association on the Need for FDA Regulation of Blood Glucose Test Strips July 31, 2013. Available at: https://professional.diabetes.org/News-Display. aspx?TYP9&CID93129 [Last accessed August 2013]
78. Cryer PE. Hypoglycaemia in type 2 diabetes. In: Goldstein BJ, Mü ller-Wieland D, eds. Type 2 Diabetes Principles and Practice, 2nd edn. New York, NY: Informa Healthcare, 2008:232
79. Walsh J, Robert R, Varma C, Bailey T. Using insulin. San Diego: Torrey Pines Press; 2003